Sponsors (2)
The bill strengthens drug supply-chain transparency and makes import labeling simpler to speed safety responses and ease compliance, but it creates new compliance and administrative costs that may raise prices, burden regulators, and could reduce customs origin transparency or expose proprietary information.
Patients, caregivers, and hospitals can identify the original manufacturer of APIs and finished drugs (via unique facility identifiers and barcode/QR links or paper), enabling faster source tracing and quicker recalls or contamination response.
Consumers and patients can access manufacturer and quantity information through barcode/QR links or on-request paper, improving informed purchasing and verification.
Drug manufacturers, importers, and hospitals can follow FDA labeling for finished imports instead of a separate customs marking regime, simplifying compliance and reducing conflicts that would otherwise cause enforcement actions or shipment delays.
Small and mid-size drug manufacturers and distributors face higher compliance costs (IT systems, searchable portals, QR linking, extra paperwork) that could be passed to consumers as higher drug prices and may reduce competition.
Manufacturers and regulators will incur administrative and transition burdens to implement and maintain searchable portals, QR code linkage, and related documentation, raising agency workload and state/federal implementation costs.
Publishing detailed facility identifiers risks exposing proprietary supply‑chain or security-sensitive information, which could harm manufacturers' competitive positions or raise security concerns.
Based on analysis of 3 sections of legislative text.
Requires finished drug and API labels (or linked portal) to disclose original manufacturers, facility identifiers, and locations, and lets FDA-compliant marks substitute for customs origin marks for qualifying drugs.
Introduced April 14, 2026 by Rich McCormick · Last progress April 14, 2026
Requires finished drug products and active pharmaceutical ingredients (APIs) to carry or link to labeling that discloses the original manufacturer(s), facility unique identifiers, and places of business; also requires APIs to have accompanying certificates of analysis with that same information. The bill lets manufacturers satisfy certain customs country-of-origin marking rules for qualifying finished drugs by using the FDA-compliant labeling instead of the general Tariff Act marks. The law directs the Secretary to write implementing regulations, allows labels to use links or barcodes to a searchable electronic portal, requires paper copies or package-insert availability on request, and delays application until at least one year after final regulations are published and then applies to drugs manufactured on or after that effective date.